Role of high expression of IL-9 in prognosis of CLL

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 2, 2014, Pages 716-721

  Chen, Na ^a   Lv, Xiao ^a   Li, Peipei ^a   Lu, Kang ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; IL 9; Prognosis

Indexed keywords

IL9 PROTEIN, HUMAN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 9; MESSENGER RNA; PROTEIN KINASE ZAP 70; TUMOR MARKER; ZAP70 PROTEIN, HUMAN;

ARTICLE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMAN; IL-9; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; MALE; MIDDLE AGED; MONONUCLEAR CELL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

CHRONIC LYMPHOCYTIC LEUKEMIA; IL-9; PROGNOSIS;

BLOTTING, WESTERN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; INTERLEUKIN-9; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84907738598     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L, Efremov DG. Overexpression of the autoimmunity-associated phosphatase PTPN-22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood 2012; 119: 6278-6287
2. Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 2012; 5: 55
3. Fecteau JF, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood 2013; 121: 971-974
4. Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013; 27: 142-149
5. Samuel S, Beljanski V, Van Grevenynghe J, Richards S, Ben Yebdri F, He Z, Nichols C, Belgnaoui SM, Steel C, Goulet ML, Shamy A, Brown D, Abesada G, Haddad EK, Hiscott J. BCL-2 Inhibitors Sensitize Therapy-resistant Chronic Lymphocytic Leukemia Cells to VSV Oncolysis. Mol Ther 2013; 21: 1413-1423
6. Fang C, Zhuang Y, Wang L, Fan L, Wu YJ, Zhang R, Zou ZJ, Zhang LN, Yang S, Xu W, Li JY. High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia. Cancer Sci 2013; 104: 996-1001
7. Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L, Renauld JC. Acute lymphoblastic leukemia-associated JA-K1 mutants activate the Janus kinase/STAT pathway viainterleukin-9 receptor alpha homodimers. J Biol Chem 2009; 284: 6773-6781
8. Wiener Z, Falus A, Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice. Cytokine 2004; 26: 122-130
9. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010; 10: 683-687
10. Bittner C, Merz H, Krokowski M, Briese J, Wiedemann GJ, Feller AC. [New immunotherapeutic approaches for the treatment of anaplastic large cell lymphoma in a mouse model]. Verh Dtsch Ges Pathol 2000; 84: 187-198
11. Renauld JC, van der Lugt N, Vink A, van Roon M, Godfraind C, Warnier G, Merz H, Feller A, Berns A, Van Snick J. Thymic lymphomas in interleukin 9 transgenic mice. Oncogene 1994; 9: 1327-1332
12. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, Herin M, Noel H, Kadin M, Mueller-Hermelink HK, Van Snick J, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 1991; 78: 1311-1317
13. Nagato T, Kobayashi H, Kishibe K, Takahara M, Ogino T, Ishii H, Oikawa K, Aoki N, Sato K, Kimura S, Shimizu N, Tateno M, Harabuchi Y. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 2005; 11: 8250-8257
14. Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, van Snick J, Sundstrom C, Enblad G, Nilsson G. Increased serum levels of interleukin-9 correlate to negative prognostic fac tors in Hodgkin's lymphoma. Leukemia 2003; 17: 2513-2516
15. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008; 112: 4384-4399
16. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 2006; 108: 2407-2415
17. Renauld JC, Vink A, Louahed J, Van Snick J. Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. Blood 1995; 85: 1300-1305
18. Feng LL, Gao JM, Li PP, Wang X. IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in B-cell non-hodgkin's lymphoma. J Clin Immunol 2011; 31: 1084-1094
19. Lv X, Feng L, Fang X, Jiang Y, Wang X. Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. Int J Clin Exp Pathol 2013; 6: 911-916
20. Chen J, Petrus M, Bryant BR, Phuc Nguyen V, Stamer M, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 2008; 111: 5163-5172
21. Matsushita K, Arima N, Ohtsubo H, Fujiwara H, Hidaka S, Fukumori J, Tanaka H. Frequent expression of interleukin-9 mRNA and infrequent involvement of interleukin-9 in proliferation of primary adult T-cell leukemia cells and HTLV-I infected T-cell lines. Leuk Res 1997; 21: 211-216
22. Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR, Chen J, Sato N, Tagaya Y, Morris JC, Janik JE, Jacobson S, Waldmann TA. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011; 117: 1938-1946